# Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery Stenosis: 6 versus 12 Months

**Authors:** Tau Sarra Hartikainen, Sina Mertins, Max Behrens, Franz-Josef Neumann, Christian Marc Valina, Nikolaus Löffelhardt, Faridun Daniel Rahimi Nedjat, Philipp Breitbart, Kilian Franke, Dirk Westermann, Miroslaw Ferenc

PMC · DOI: 10.3390/jcm13185449 · Journal of Clinical Medicine · 2024-09-13

## TL;DR

This study compares 6-month and 12-month dual antiplatelet therapy after heart procedures and finds no significant difference in outcomes.

## Contribution

The study provides new evidence on optimal DAPT duration for uLMCA PCI in stable angina patients.

## Key findings

- No significant difference in the primary endpoint between 6 and 12 months of DAPT.
- Stent thrombosis and bleeding rates were comparable in both groups.
- Results suggest 6 months of DAPT is sufficient for uLMCA PCI in stable angina patients.

## Abstract

Background/Objectives: For patients with percutaneous coronary intervention (PCI) of an unprotected left main coronary artery (uLMCA) stenosis, the optimal duration of dual antiplatelet therapy (DAPT) remains a matter of debate. The purpose of this study was to compare clinical outcomes of 6- versus 12-month DAPT duration in patients with PCI of an uLMCA and stable angina. Methods: In this retrospective analysis, we included consecutive patients of our centre who underwent PCI of uLMCA stenosis for stable angina and who received DAPT with acetylsalicylic acid and clopidogrel for either 6 or 12 months. The primary endpoint was the composite of all-cause mortality, myocardial infarction, and target lesion revascularization at one year. Secondary endpoints included individual components of the primary endpoint, definite/probable stent thrombosis, and bleeding. Clinical outcomes were assessed by unadjusted analysis and by inverse probability of treatment weighting (IPTW). Results: Out of 984 included patients, 339 (34.5%) received DAPT for 6 months and 645 (65.5%) for 12 months. The primary endpoint occurred in 51 patients (15.2%) in the 6-month group and in 104 (16.3%) in the 12-month group (p = 0.674). Incidences of stent thrombosis (0.9% versus 0.3%, p = 0.224) and BARC 3,4,5 bleeding (6% versus 5.8%, p = 0.808) were also comparable in both groups. We found no significant differences in the primary endpoint and its components or BARC 3,4,5 bleeding between 6 and 12 months. Conclusions: Our findings do not support the extension of DAPT beyond 6 months after PCI for uLMCA in patients with stable angina.

## Linked entities

- **Chemicals:** acetylsalicylic acid (PubChem CID 2244), clopidogrel (PubChem CID 2806)
- **Diseases:** myocardial infarction (MONDO:0005068)

## Full-text entities

- **Diseases:** left main coronary artery (uLMCA) stenosis (MESH:D003324), bleeding (MESH:D006470), myocardial infarction (MESH:D009203), Coronary Artery Stenosis (MESH:D023921), stent thrombosis (MESH:D013927), stenosis (MESH:D003251), stable angina (MESH:D060050)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11431983/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11431983/full.md

## References

26 references — full list in the complete paper: https://tomesphere.com/paper/PMC11431983/full.md

---
Source: https://tomesphere.com/paper/PMC11431983